LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES
1
1. Cairncross JG, Macdonald DR. Successful chemotherapy for
recurrent malignant oligodendroglioma. Ann Neurol 1988;
3:460-464.
33. Gannett DE, Wisbeck WM, Silbergeld DL, Berger MS. The role of
postoperative irradiation in the treatment of oligodendroglioma.
Int J Radiat Oncol Biol Phys 1994; 30:567-573.
2
1
2. Cairncross J, Macdonald D, Ludwin S, et al. for the National Cancer
Institute of Canada Clinical Trial Group. Chemotherapy for
anaplastic oligodendroglioma. J Clin Oncol 1994; 12:2013-2021.
3. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine,
CCNU and vincristine (PCV-3) combination chemotherapy in the
treatment of malignant brain tumors. Cancer Treat Rep 1980;
34. Mork SJ, Lindergaard KF, Halvorsen TB, et al. Oligodendroglioma:
incidence and biological behavior in a defined population. J
Neurosurg 1985; 63:881-889.
35. Nijjar TS, Simpson WJ, Gadalla T, McCartney M.
Oligodendroglioma. The Princess Margaret Hospital experience
(1958-1984). Cancer 1993; 71:4002-4006.
1
6
4:237-241.
36. Shaw EG, Scheithauer BW, O’Fallon JR. Supratentorial gliomas: a
comparative study by grade and histologic type. J Neurooncol
1997; 31/3:273-278.
1
4. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross
JG. Salvage chemotherapy for oligodendroglioma. J Neurosurg
1
996; 85:597-601.
37. Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH.
Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg
1992; 76:428-434.
38. Paleologos N, Cairncross JG. Treatment of oligodendroglioma: an
update. Neurooncology 1999; 1:61-68.
39. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic
value of the proliferation-related antigen KI-67 in
oligodendrogliomas. Cancer 1996; 78:1107-1113.
40. Ishikura R, Ando K, Tominaga S, et al. CTdiagnosis of hyperdense
intracranial neoplasms: review of the literature. Nippon Igaku
Hoshasen Gakkai Zasshi 1999; 59:105-112.
41. Daumas-Duport C, Scheithauer B, O’Fallon J, Kelly P. Grading of
astrocytomas: a simple and reproducible method. Cancer 1988;
64:2152-2165.
42. Smith MT, Ludwig CL, Godfrey AD, Armbrustmatcher VW.
Grading of oligodendrogliomas. Cancer 1983; 52:2107-2114.
43. Kros JM, Troost D, van Eden CG, van der Werf JM, Uylings HBM.
Oligodendroglioma: a comparison of two grading systems.
Cancer 1988; 61:2251-2259.
44. Alvord EC. Is necrosis helpful in the grading of gliomas? Editorial
opinion. LNeuropathol Exp Neurol 1992; 51:127-132.
45. Coons SW, Johnson PC. Regional heterogeneity in the proliferative
activity of human gliomas as measured by the KI-67 labeling
index. J Neuropathol Exp Neurol 1993; 52:609-618.
46. Earnest F III, Kernohan JW, Craig WM. Oligodendrogliomas: a
review of two hundred cases. Arch Neurol Psychiatr 1950;
63:964-976.
1
5. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemo-
therapy for newly diagnosed aggressive oligodendroglioma. Ann
Neurol 1990; 27:573-574.
1
6. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendro-
glioma responds to chemotherapy. Neurology 1996; 46:203-207.
7. Glass J, Hochberg FH, Gruber ML, et al. The treatment of
oligodendrogliomas and mixed oligodendroglioma-astrocytomas
with PCV chemotherapy. J Neurosurg 1992; 76:741-745.
8. Kyritsis AP, Yung WK, Bruner J, Gleason MJ, Levin VA. The
treatment of anaplastic oligodendrogliomas and mixed gliomas.
Neurosurg 1993; 32:365-371.
9. Kirby S, Macdonald D, Fisher B, Gaspar L, Cairncross G.
Preradiation chemotherapy for malignant glioma in adults. Can J
Neurol Sci 1996; 23:123-127.
0. Kim L, Hochberg FH, Thornton AF, et al. Procarbazine, lomustine,
and vincristine (PCV) chemotherapy for grade III and grade IV
oligoastrocytomas. J Neurosurg 1996; 85:602-607.
1. Brown M, Cairncross JG, Vick NA, et al. Differential response of
recurrent oligodendrogliomas versus astrocytomas to intravenous
melphalan. Neurology 1990; 40(suppl 1):397-398.
2. Saarinen UM, Pihko H, Makipernaa A. High-dose thiotepa with
autologous bone marrow rescue in recurrent malignant
oligodendroglioma: a case report. J Neurooncol 1990; 9:57-62.
3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic
predictors of chemotherapeutic response and survival in patients
with anaplastic oligodendrogliomas. J Nat Can Inst 1998;
1
1
1
2
2
2
2
9
0:1473-1479.
47. Coons SW, Johnson PC, Pearl DK. The prognostic significance of
KI-67 labeling indices for oligodendrogliomas. Neurosurg 1997;
41:878-884.
48. Coons SW, Johnson PC, Pearl DK, Olafsen AG. Prognostic
significance of flow cytometry deoxyribonucleic acid analysis of
human oligodendrogliomas. Neurosurg 1994; 34:680-687.
49. Heegaard S, Sommer HM, Broholm H, Braendstrup O. Proliferating
cell nuclear antigen and KI-67 immunohistochemistry of
oligodendrogliomas with special reference to prognosis. Cancer
1995; 76:1809-1813.
50. Kros JM, Schouten WCD, Janssen PJA, van der Kwast TH.
Proliferation of gemistocytic cells and glial fibrillary acidic
protein (GFAP)-positive oligodendroglial cells in gliomas: a
MIB-1/GFAP double labeling study. Acta Neuropathol 1996;
91:99-103.
51. Kros JM, van Eden CG, Vissers CJ, Mulder AH, van der Kwast TH.
Prognostic relevance of DNA flow cytometry in
oligodendroglioma. Cancer 1992; 69:1791-1798.
2
2
2
2
4. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive
oligodendrogliomas: a chemosensitive tumor. Neurosurg 1992;
3
1:78-82.
5. Daumas-Duport C, Tucker M-L, Kolles H, et al. Oligodendro-
gliomas. Part II: a new grading system based on morphological
and imaging criteria. J Neurooncol 1997; 34: 61-78.
6. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG.
Response criteria for phase II studies of supratentorial malignant
glioma. J Clin Oncol 1990; 7:1277-1280.
7. Kros JM, Pieterman H, van Eden CG, Avezaat CJ.
Oligodendroglioma: the Rotterdam-Dijkzigt experience.
Neurosurg 1994; 34:959-966.
8. Schiffer D, Dutto A, Cavalla P, et al. Prognostic factors in
oligodendroglioma. Can J Neurol Sci 1997; 24:313-319.
9. Shaw EG, Scheithauer BW, O’Fallon JR, Davis DH. Mixed
oligoastrocytomas: a survival and prognostic factor analysis.
Neurosurg 1994; 34:577-582.
2
2
3
3
3
0. Shimizu KT, Tran LM, Mark RJ, Selch MT. Management of
52. Donahue B, Scott CB, Nelson JS, et al. Influence of an
oligodendroglial component on the survival of patients with
anaplastic astrocytomas: a report of Radiation Therapy Oncology
Group 83-02. Int J Rad Oncol Bio Phys 1997; 38:911-914.
53. Krouwer HG, Van-Duinen SG, Kamphorst W, van-der-Valk P, Algra
A. Oligoastrocytomas: a clinicopathological study of 52 cases. J
Neurooncol 1997; 33:223-238.
oligodendrogliomas. Radiology 1993; 186:569-572.
1. Burger PC, Rawlings CE, Cox EB, et al.. Clinicopathologic
correlations in the oligodendroglioma. Cancer 1987; 59:1345-1352.
2. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A. Cerebral
oligodendroglioma: prognostic factors and life history. Neurosurg
1
994; 35:1018-1035
Volume 28, No. 3 – August 2001
223